Association of Genetic Characteristics with Response to Venetoclax Plus Hypomethylating Agents in Relapsed and Refractory Acute Myeloid Leukemia

被引：2
|
作者：
Weng, Guangyang [1 ,2 ]
Zhang, Yu [1 ]
Yu, Guopan [1 ]
Xu, Na [1 ]
Sun, Zhiqiang [3 ]
Lin, Dongjun [4 ]
Liang, Xinquan [5 ]
Deng, Lan [6 ]
Xiao, Jie [7 ]
Zhang, Hongyu [8 ]
Guo, Ziwen [9 ]
Jin, Hua [1 ]
Du, Xin [10 ]
Liu, Qifa [1 ]
机构：
[1] Southern Med Univ, Nanfang Hosp, Dept Hematol, Guangzhou, Peoples R China
[2] Shenzhen Univ, Peoples Hosp Shenzhen 2, Affiliated Hosp 1, Dept Hematol, Shenzhen, Peoples R China
[3] Southern Med Univ, Shenzhen Hosp, Dept Hematol, Shenzhen, Peoples R China
[4] Sun Yat Sen Univ, Affiliated Hosp 7, Dept Hematol, Shenzhen, Peoples R China
[5] First Peoples Hosp Chenzhou, Dept Hematol, Chenzhou, Peoples R China
[6] Shanghai Jiao Tong Univ, Sch Med, Shanghai Peoples Hosp 9, Dept Hematol, Shanghai, Peoples R China
[7] Sun Yat Sen Univ, Sun Yat Sen Mem Hosp, Dept Hematol, Guangzhou, Peoples R China
[8] Peking Univ, Dept Hematol, Shenzhen Hosp, Shenzhen, Peoples R China
[9] Zhongshan City Peoples Hosp, Dept Hematol, Zhongshan, Peoples R China
[10] Shenzhen Univ, Affiliated Hosp 1, Shenzhen Peoples Hosp 2, Dept Hematol, Shenzhen, Peoples R China
来源：
BLOOD | 2022年 / 140卷
关键词：
D O I：
10.1182/blood-2022-158762
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
下载
收藏
页码：2025 / 2026
页数：2
相关论文
共 50 条
  • [31] AVALON: The Italian cohort study on real-life efficacy of hypomethylating agents plus venetoclax in newly diagnosed or relapsed/refractory patients with acute myeloid leukemia
    Todisco, Elisabetta
    Papayannidis, Cristina
    Fracchiolla, Nicola
    Petracci, Elisabetta
    Zingaretti, Chiara
    Vetro, Calogero
    Martelli, Maria Paola
    Zappasodi, Patrizia
    Di Renzo, Nicola
    Gallo, Susanna
    Audisio, Ernesta
    Griguolo, Davide
    Cerchione, Claudio
    Selleri, Carmine
    Mattei, Daniele
    Bernardi, Massimo
    Fumagalli, Monica
    Rizzuto, Giuliana
    Facchini, Luca
    Basilico, Claudia Maria
    Manfra, Ilenia
    Borlenghi, Erika
    Cairoli, Roberto
    Salutari, Prassede
    Gottardi, Michele
    Molteni, Alfredo
    Martini, Vincenza
    Lunghi, Monia
    Fianchi, Luana
    Cilloni, Daniela
    Lanza, Francesco
    Abruzzese, Elisabetta
    Cascavilla, Nicola
    Rivellini, Flavia
    Ferrara, Felicetto
    Maurillo, Luca
    Nanni, Jacopo
    Romano, Alessandra
    Cardinali, Valeria
    Gigli, Federica
    Roncoroni, Elisa
    Federico, Vincenzo
    Marconi, Giovanni
    Volpi, Roberta
    Sciume, Mariarita
    Tarella, Corrado
    Rossi, Giuseppe
    Martinelli, Giovanni
    CANCER, 2023, 129 (07) : 992 - 1004
  • [32] PRELIMINARY TREATMENT EXPERIENCE OF ACUTE MYELOID LEUKAEMIA WITH VENETOCLAX IN ASSOCIATION WITH FIRST-LINE HYPOMETHYLATING AGENTS OR RELAPSED/REFRACTORY DISEASE
    Jimenez, Vicente C.
    Bataller, A.
    Castano, Diez S.
    Guijarro, F.
    Esteban, D.
    Gomez, Hernando M.
    Castillo, Giron C. M.
    Charry, P.
    Palomino, A.
    Garrote, M.
    Rivero, A.
    Moreno, D. F.
    Martinez, Roca A. P.
    Alvarez, Larran A.
    Socoro, Yuste N.
    Riu, G.
    Monge, I
    Carcelero, E.
    Diaz, Beya M.
    Esteve, J.
    HAEMATOLOGICA, 2020, 105 : 47 - 48
  • [33] The efficacy of venetoclax and hypomethylating agents in acute myeloid leukemia with extramedullary involvement
    Otoukesh, Salman
    Zhang, Jianying
    Nakamura, Ryotaro
    Stein, Anthony S.
    Forman, Stephen J.
    Marcucci, Guido
    Pullarkat, Vinod
    Aldoss, Ibrahim
    LEUKEMIA & LYMPHOMA, 2020, 61 (08) : 2020 - 2023
  • [34] Efficacy of hypomethylating agents and Venetoclax in unfit patients with acute myeloid leukemia
    Rieger, M.
    Manz, M. G.
    Muller, R.
    Theocharides, A. P. A.
    Schwotzer, R.
    SWISS MEDICAL WEEKLY, 2020, : 17S - 17S
  • [35] Venetoclax Combination Therapy in Relapsed/Refractory Acute Myeloid Leukemia
    Brancati, Serena
    Gozzo, Lucia
    Romano, Giovanni Luca
    Vetro, Calogero
    Dulcamare, Ilaria
    Maugeri, Cinzia
    Parisi, Marina
    Longo, Laura
    Vitale, Daniela Cristina
    Di Raimondo, Francesco
    Drago, Filippo
    BLOOD, 2021, 138
  • [36] Venetoclax with decitabine or azacitidine in relapsed or refractory acute myeloid leukemia
    Bouligny I.M.
    Murray G.
    Doyel M.
    Patel T.
    Boron J.
    Tran V.
    Gor J.
    Hang Y.
    Alnimer Y.
    Ho T.
    Zacholski K.
    Venn C.
    Wages N.A.
    Grant S.
    Maher K.R.
    Medical Oncology, 41 (3)
  • [37] Outcomes of relapsed or refractory acute myeloid leukemia after front-line hypomethylating agent and venetoclax regimens
    Maiti, Abhishek
    Rausch, Caitlin R.
    Cortes, Jorge E.
    Pemmaraju, Naveen
    Daver, Naval G.
    Ravandi, Farhad
    Garcia-Manero, Guillermo
    Borthakur, Gautam
    Naqvi, Kiran
    Ohanian, Maro
    Short, Nicholas J.
    Alvarado, Yesid
    Kadia, Tapan M.
    Takahashi, Koichi
    Yilmaz, Musa
    Jain, Nitin
    Kornblau, Steven
    Montalban-Bravo, Guillermo
    Sasaki, Koji
    Andreeff, Michael
    Bose, Prithviraj
    Ferrajoli, Alessandra
    Issa, Ghayas C.
    Jabbour, Elias J.
    Masarova, Lucia
    Thompson, Philip A.
    Wang, Sa
    Konoplev, Sergej
    Pierce, Sherry A.
    Ning, Jing
    Qiao, Wei
    Welch, John S.
    Kantarjian, Hagop M.
    DiNardo, Courtney D.
    Konopleva, Marina Y.
    HAEMATOLOGICA, 2021, 106 (03) : 894 - 898
  • [38] Venetoclax in patients with acute myeloid leukemia refractory to hypomethylating agents-a multicenter historical prospective study
    Ram, Ron
    Amit, Odelia
    Zuckerman, Tsila
    Gurion, Ronit
    Raanani, Pia
    Bar-On, Yael
    Avivi, Irit
    Wolach, Ofir
    ANNALS OF HEMATOLOGY, 2019, 98 (08) : 1927 - 1932
  • [39] Proteomics for optimizing therapy in acute myeloid leukemia: venetoclax plus hypomethylating agents versus conventional chemotherapy
    de Camargo Magalhaes, Eduardo Sabino
    Hubner, Stefan Edward
    Brown, Brandon Douglas
    Qiu, Yihua
    Kornblau, Steven Mitchell
    LEUKEMIA, 2024, 38 (05) : 1046 - 1056
  • [40] Proteomics for optimizing therapy in acute myeloid leukemia: venetoclax plus hypomethylating agents versus conventional chemotherapy
    Eduardo Sabino de Camargo Magalhães
    Stefan Edward Hubner
    Brandon Douglas Brown
    Yihua Qiu
    Steven Mitchell Kornblau
    Leukemia, 2024, 38 : 1046 - 1056
12345